Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

Authors

CATTANEO Chiara SALMANTON-GARCIA Jon MARCHESI Francesco EL-ASHWAH Shaimaa ITRI Federico WEINBERGEROVÁ Barbora GOMES Da Silva Maria DARGENIO Michelina DAVILA-VALLS Julio MARTIN-PEREZ Sonia FARINA Francesca JAAP Van Doesum VALKOVIC Toni BESSON Caroline POULSEN Christian Bjorn LOPEZ-GARCIA Alberto ZAK Pavel SCHONLEIN Martin PIUKOVICS Klara JAKSIC Ozren CABIRTA Alba ALI Natasha SILI Uluhan FRACCHIOLLA Nicola DRAGONETTI Giulia ADZIC-VUKICEVIC Tatjana MARCHETTI Monia MACHADO Marina GLENTHOJ Andreas FINIZIO Olimpia DEMIRKAN Fatih BLENNOW Ola TISI Maria Chiara OMRANI Ali S NAVRATIL Milan RACIL Zdenek NOVAK Jan MAGLIANO Gabriele JIMENEZ Moraima GARCIA-VIDAL Carolina ERBEN Nurettin ILARIA Del Principe Maria BUQUICCHIO Caterina BERGANTIM Rui BATINIC Josip AL-KHABORI Murtadha VERGA Luisa SZOTKOWSKI Tomas SAMARKOS Michail ORMAZABAL-VELEZ Irati MEERS Stef MAERTENS Johan PINCZES Laszlo Imre HOENIGL Martin DRGONA Lubos CUCCARO Annarosa BILGIN Yavuz M AUJAYEB Avinash RAHIMLI Laman GRAFE Stefanie SCIUME Mariarita MLADENOVIC Milos COLAK Gokce Melis SACCHI Maria Vittoria NORDLANDER Anna VENEMYR Caroline Berg HANAKOVA Michaela GARCIA-POUTON Nicole EMARAH Ziad ZAMBROTTA Giovanni Paolo Maria RODRIGUES Raquel Nunes CORDOBA Raul MENDEZ Gustavo-Adolfo BIERNAT Monika M CORNELY Oliver A PAGANO Livio

Year of publication 2022
Type Article in Periodical
Magazine / Source Cancers
MU Faculty or unit

Faculty of Medicine

Citation
web https://www.mdpi.com/2072-6694/14/22/5530
Doi http://dx.doi.org/10.3390/cancers14225530
Keywords haematological malignancy onset; COVID-19; treatment; outcome; prognostic factors
Description Simple Summary Patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 are an even greater challenge for hematologists. To better clarify their outcome, we describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Overall, 343 (76.2%) patients received treatment for HM, and an overall response rate was observed in 140 (40.8%) patients after the first line of treatment. Thirty-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004). Statistical analysis showed that, together with age, severe/critical COVID-19, >= 2 comorbidities, lack of HM treatment was an independent risk factors for mortality. These observations suggest the importance of HM treatment in these patients; therefore, it should be delivered as soon as possible for patients requiring immediate therapy. Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, >= 2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.

You are running an old browser version. We recommend updating your browser to its latest version.

More info

By clicking “Accept Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookie Settings

Necessary Only Accept Cookies